Anemia

Affymax presents results from phase II trial of Hematide in anemic cancer patients

Published in Cancer Law Weekly, January 13th, 2007

Affymax, Inc., a clinical-stage pharmaceutical company, announced the presentation of results from an ongoing phase II, open-label, multicenter, dose-finding clinical trial of Hematide in anemic cancer patients receiving chemotherapy.

Hematide, a novel peptide-based drug designed to stimulate the production of red blood cells, is the company's first product candidate to enter the clinic. Hematide is being evaluated in phase II clinical trials for the treatment of anemia associated with chronic kidney disease and in anemic cancer patients undergoing chemotherapy. The data were presented in a poster session (Abstract #1290) at the 48th Annual Meeting of the American...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Law Weekly

Source: Cancer Law Weekly (2007-01-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry